Crossmark Global Holdings Inc. acquired a new stake in shares of Phibro Animal Health Corp (NASDAQ:PAHC) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 7,540 shares of the company’s stock, valued at approximately $253,000.
Several other institutional investors and hedge funds also recently made changes to their positions in PAHC. Eagle Asset Management Inc. acquired a new position in Phibro Animal Health during the third quarter valued at $5,781,000. Ameriprise Financial Inc. lifted its position in Phibro Animal Health by 26.7% during the third quarter. Ameriprise Financial Inc. now owns 430,656 shares of the company’s stock valued at $15,958,000 after purchasing an additional 90,660 shares during the period. Copper Rock Capital Partners LLC lifted its position in Phibro Animal Health by 9.6% during the fourth quarter. Copper Rock Capital Partners LLC now owns 631,876 shares of the company’s stock valued at $21,326,000 after purchasing an additional 55,235 shares during the period. Prudential Financial Inc. lifted its position in Phibro Animal Health by 59.0% during the third quarter. Prudential Financial Inc. now owns 141,760 shares of the company’s stock valued at $5,253,000 after purchasing an additional 52,590 shares during the period. Finally, Vanguard Group Inc. lifted its position in Phibro Animal Health by 3.0% during the second quarter. Vanguard Group Inc. now owns 1,780,880 shares of the company’s stock valued at $65,982,000 after purchasing an additional 51,474 shares during the period. 47.38% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts recently issued reports on the stock. Zacks Investment Research downgraded shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. BidaskClub upgraded shares of Phibro Animal Health from a “strong sell” rating to a “sell” rating in a research report on Saturday, January 6th. Morgan Stanley upped their price objective on shares of Phibro Animal Health from $30.00 to $36.00 and gave the stock an “underweight” rating in a research report on Wednesday, February 7th. Piper Jaffray Companies reiterated a “buy” rating and issued a $42.00 price objective on shares of Phibro Animal Health in a research report on Friday, November 10th. Finally, ValuEngine downgraded shares of Phibro Animal Health from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Phibro Animal Health currently has an average rating of “Hold” and an average target price of $38.20.
Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Monday, February 5th. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.38 by $0.06. The business had revenue of $205.90 million during the quarter, compared to the consensus estimate of $194.90 million. Phibro Animal Health had a net margin of 7.90% and a return on equity of 40.49%. The company’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.39 earnings per share. sell-side analysts expect that Phibro Animal Health Corp will post 1.69 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, March 7th will be given a $0.10 dividend. The ex-dividend date is Tuesday, March 6th. This represents a $0.40 dividend on an annualized basis and a dividend yield of 1.04%. Phibro Animal Health’s dividend payout ratio (DPR) is currently 26.14%.
In other news, insider Dean J. Warras sold 10,000 shares of the business’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $35.62, for a total transaction of $356,200.00. Following the completion of the sale, the insider now owns 10,000 shares of the company’s stock, valued at $356,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Larry Lee Miller sold 54,572 shares of the business’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $35.36, for a total transaction of $1,929,665.92. Following the sale, the chief operating officer now directly owns 8,582 shares of the company’s stock, valued at approximately $303,459.52. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,754 shares of company stock valued at $2,789,185. Insiders own 51.88% of the company’s stock.
WARNING: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3222897/crossmark-global-holdings-inc-acquires-new-holdings-in-phibro-animal-health-corp-pahc.html.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.
Want to see what other hedge funds are holding PAHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phibro Animal Health Corp (NASDAQ:PAHC).
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.